DK0784476T3 - Behandling af multipel sklerose (MS) og andre demyelinisationstilstande under anvendelse af lofepramin i kombination med L-phenylalanin, tyrosin eller tryptophan og eventuelt en vitamin B12-forbindelse - Google Patents

Behandling af multipel sklerose (MS) og andre demyelinisationstilstande under anvendelse af lofepramin i kombination med L-phenylalanin, tyrosin eller tryptophan og eventuelt en vitamin B12-forbindelse

Info

Publication number: DK0784476T3
Authority: DK; Denmark
Prior art keywords: phenylalanine; tyrosine; combination; multiple sclerosis; lofepramine
Prior art date: 1994-10-05

Application number

DK95933488T

Other languages

English (en)

Inventor

Cari Loder

Original Assignee

Cari Loder

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-05

Filing date

1995-10-05

Publication date

2003-03-17

1994-10-05 Priority claimed from GB9420116A external-priority patent/GB9420116D0/en

1995-04-26 Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en

1995-10-05 Application filed by Cari Loder filed Critical Cari Loder

2003-03-17 Application granted granted Critical

2003-03-17 Publication of DK0784476T3 publication Critical patent/DK0784476T3/da

Links

201000006417 multiple sclerosis Diseases 0.000 title abstract 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title abstract 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title abstract 2
QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 title 1
208000016192 Demyelinating disease Diseases 0.000 title 1
206010012305 Demyelination Diseases 0.000 title 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title 1
229930003779 Vitamin B12 Natural products 0.000 title 1
SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 title 1
229960002813 lofepramine Drugs 0.000 title 1
239000011715 vitamin B12 Substances 0.000 title 1
235000019163 vitamin B12 Nutrition 0.000 title 1
-1 vitamin B12 compound Chemical class 0.000 title 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
229940123445 Tricyclic antidepressant Drugs 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
201000002491 encephalomyelitis Diseases 0.000 abstract 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
239000003029 tricyclic antidepressant agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Fodder In General (AREA)
Control Of Indicators Other Than Cathode Ray Tubes (AREA)
Control Of El Displays (AREA)

DK95933488T 1994-10-05 1995-10-05 Behandling af multipel sklerose (MS) og andre demyelinisationstilstande under anvendelse af lofepramin i kombination med L-phenylalanin, tyrosin eller tryptophan og eventuelt en vitamin B12-forbindelse DK0784476T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9420116A GB9420116D0 (en)	1994-10-05	1994-10-05	A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GBGB9508482.8A GB9508482D0 (en)	1995-04-26	1995-04-26	A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
PCT/GB1995/002361 WO1996011009A1 (en)	1994-10-05	1995-10-05	Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound

Publications (1)

Publication Number	Publication Date
DK0784476T3 true DK0784476T3 (da)	2003-03-17

Family

ID=26305745

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95933488T DK0784476T3 (da)	1994-10-05	1995-10-05	Behandling af multipel sklerose (MS) og andre demyelinisationstilstande under anvendelse af lofepramin i kombination med L-phenylalanin, tyrosin eller tryptophan og eventuelt en vitamin B12-forbindelse

Country Status (19)

Country	Link
US (2)	US6096737A (da)
EP (1)	EP0784476B1 (da)
JP (1)	JPH10508583A (da)
AT (1)	ATE227124T1 (da)
AU (1)	AU710339B2 (da)
CA (1)	CA2200761C (da)
CZ (1)	CZ293873B6 (da)
DE (1)	DE69528773T2 (da)
DK (1)	DK0784476T3 (da)
ES (1)	ES2184808T3 (da)
FI (1)	FI116659B (da)
HU (1)	HU225493B1 (da)
IS (1)	IS1956B (da)
NO (1)	NO314486B1 (da)
NZ (1)	NZ293642A (da)
PL (1)	PL181802B1 (da)
PT (1)	PT784476E (da)
SK (1)	SK281932B6 (da)
WO (1)	WO1996011009A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69715899T2 (de) *	1996-07-05	2003-05-28	The Wwk Trust, Kent	Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten
GB9617990D0 (en) *	1996-08-29	1996-10-09	Scotia Holdings Plc	Treatment of pain
EP0835660A1 (en) *	1996-10-14	1998-04-15	Gaston Edmond Filomena Merckx	Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US7232830B2 (en) *	1998-06-26	2007-06-19	Elaine A Delack	Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) *	1999-02-24	1999-04-21	Worsley Andrew P	Composition for the treatment of pain
GB9906808D0 (en) *	1999-03-24	1999-05-19	Kilgowan Limited	Formulation for treatment of pain
GB2355191A (en) *	1999-10-12	2001-04-18	Laxdale Ltd	Combination formulations for fatigue, head injury and strokes
AU2001279313B2 (en)	2000-08-04	2007-03-01	Ampio Pharmaceuticals, Inc.	Method of using diketopiperazines and composition containing them
US8394813B2 (en)	2000-11-14	2013-03-12	Shire Llc	Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) *	2001-04-05	2002-10-10	Pfizer Inc.	Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en)	2002-07-10	2002-08-21	Arachnova Therapeutics Ltd	New therapeutic use
US7169752B2 (en) *	2003-09-30	2007-01-30	New River Pharmaceuticals Inc.	Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) *	2002-03-14	2004-12-21	Duane Bennett	Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
ATE520981T1 (de)	2002-10-02	2011-09-15	Dmi Biosciences Inc	Diagnose und überwachung von krankheiten
WO2004073614A2 (en) *	2003-02-14	2004-09-02	Combinatorx, Incorporated	Combination therapy for the treatment of immunoinflammatory disorders
CA3050734A1 (en)	2003-05-15	2004-12-02	Ampio Pharmaceuticals, Inc.	Treatment of t-cell mediated diseases
GB0313630D0 (en) *	2003-06-12	2003-07-16	Wwk Trust The	Compositions for the enhanced treatment of depression
TW200522932A (en) *	2003-09-15	2005-07-16	Combinatorx Inc	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ATE552832T1 (de)	2006-02-24	2012-04-15	Shire Llc	Antidepressivum-propharmaka
WO2009146320A1 (en)	2008-05-27	2009-12-03	Dmi Life Sciences, Inc.	Therapeutic methods and compounds
WO2011011594A2 (en) *	2009-07-23	2011-01-27	Shriners Hospitals For Children	Intracellular toll-like receptors pathways and axonal degeneration
US8507496B2 (en)	2010-09-07	2013-08-13	Dmi Acquisition Corp.	Treatment of diseases
EA027343B1 (ru)	2011-10-10	2017-07-31	Ампио Фармасьютикалз, Инк.	Имплантируемые устройства медицинского назначения с повышенной иммунной толерантностью и способы изготовления и имплантирования
EP2766029B1 (en)	2011-10-10	2020-03-25	Ampio Pharmaceuticals, Inc.	Treatment of degenerative joint disease
CA2846394A1 (en)	2011-10-28	2013-05-02	Ampio Pharmaceuticals, Inc.	Treatment of rhinitis
BR112015020469A2 (pt)	2013-03-15	2020-01-28	Ampio Pharmaceuticals Inc	Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
AU2015305611B2 (en)	2014-08-18	2020-04-23	Ampio Pharmaceuticals, Inc.	Treatment of joint conditions
US11389512B2 (en)	2015-06-22	2022-07-19	Ampio Pharmaceuticals, Inc.	Use of low molecular weight fractions of human serum albumin in treating diseases
GB2544630A (en)	2015-11-19	2017-05-24	The Wwk Trust	Combinations for the treatment of dementia, and the enhancement of cognitive function
WO2018076108A1 (en) *	2016-10-25	2018-05-03	Uti Limited Partnership	Treatment for progressive multiple sclerosis
WO2018200381A1 (en)	2017-04-25	2018-11-01	Temple Otorongo Llc	Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (en) *	2017-07-18	2019-01-23	Centre National De La Recherche Scientifique	Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1497306A (en) *	1975-07-03	1978-01-05	Leo Ab	Preparation of lofepramine and its hydrochloride
GB2082910A (en) *	1980-08-28	1982-03-17	Berk Pharmaceuticals Ltd	Anti-depressant compositions
US4409243A (en) *	1981-11-09	1983-10-11	Julian Lieb	Treatment of auto-immune and inflammatory diseases
GB2129299A (en) *	1982-11-09	1984-05-16	Alec James Coppen	Pharmaceutical compositions
DE3519687A1 (de) *	1985-06-01	1986-12-04	Veit Arend	Aminosaeuren enthaltendes arzneimittel
US4650789A (en) *	1985-10-15	1987-03-17	Commonwealth Medical Corporation Of America	Method and composition for increasing production of serotonin
US4843071A (en) *	1986-12-05	1989-06-27	Serotonin Industries Of Charleston	Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) *	1992-02-12	1998-09-24	Kragler Peter	Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

1995
- 1995-10-05 ES ES95933488T patent/ES2184808T3/es not_active Expired - Lifetime
- 1995-10-05 EP EP95933488A patent/EP0784476B1/en not_active Expired - Lifetime
- 1995-10-05 JP JP8512415A patent/JPH10508583A/ja active Pending
- 1995-10-05 SK SK438-97A patent/SK281932B6/sk not_active IP Right Cessation
- 1995-10-05 DK DK95933488T patent/DK0784476T3/da active
- 1995-10-05 US US08/817,086 patent/US6096737A/en not_active Expired - Lifetime
- 1995-10-05 HU HU9702373A patent/HU225493B1/hu not_active IP Right Cessation
- 1995-10-05 AU AU36126/95A patent/AU710339B2/en not_active Ceased
- 1995-10-05 PT PT95933488T patent/PT784476E/pt unknown
- 1995-10-05 WO PCT/GB1995/002361 patent/WO1996011009A1/en not_active Ceased
- 1995-10-05 CZ CZ1997995A patent/CZ293873B6/cs not_active IP Right Cessation
- 1995-10-05 DE DE69528773T patent/DE69528773T2/de not_active Expired - Lifetime
- 1995-10-05 NZ NZ293642A patent/NZ293642A/xx not_active IP Right Cessation
- 1995-10-05 CA CA002200761A patent/CA2200761C/en not_active Expired - Fee Related
- 1995-10-05 AT AT95933488T patent/ATE227124T1/de not_active IP Right Cessation
- 1995-10-05 PL PL95319830A patent/PL181802B1/pl not_active IP Right Cessation
1997
- 1997-03-26 IS IS4454A patent/IS1956B/is unknown
- 1997-03-26 FI FI971290A patent/FI116659B/fi active IP Right Grant
- 1997-04-04 NO NO19971539A patent/NO314486B1/no not_active IP Right Cessation
2000
- 2000-06-01 US US09/584,401 patent/US6569850B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69528773T2 (de)	2003-09-04
HU225493B1 (en)	2007-01-29
NO971539D0 (no)	1997-04-04
SK43897A3 (en)	1998-08-05
AU3612695A (en)	1996-05-02
PT784476E (pt)	2003-03-31
FI971290A0 (fi)	1997-03-26
NO971539L (no)	1997-04-04
ES2184808T3 (es)	2003-04-16
US6096737A (en)	2000-08-01
HUT77380A (hu)	1998-04-28
WO1996011009A1 (en)	1996-04-18
US6569850B1 (en)	2003-05-27
AU710339B2 (en)	1999-09-16
EP0784476A1 (en)	1997-07-23
ATE227124T1 (de)	2002-11-15
NO314486B1 (no)	2003-03-31
NZ293642A (en)	1998-10-28
IS4454A (is)	1997-03-26
FI971290L (fi)	1997-06-02
FI116659B (fi)	2006-01-31
EP0784476B1 (en)	2002-11-06
CA2200761C (en)	2008-02-26
CZ99597A3 (en)	1997-11-12
SK281932B6 (sk)	2001-09-11
IS1956B (is)	2004-11-15
DE69528773D1 (de)	2002-12-12
PL181802B1 (en)	2001-09-28
JPH10508583A (ja)	1998-08-25
PL319830A1 (en)	1997-09-01
CZ293873B6 (cs)	2004-08-18
CA2200761A1 (en)	1996-04-18

Publication	Publication Date	Title
NO971539L (no)	1997-04-04	Behandling av multippel sklerose (MS) og andre demyelinerende tilstander ved bruk av lofepramin i kombinasjon med L-fenylalanin tyrosin eller tryptofan og eventuelt en vitamin B12-forbindelse
DK0942751T3 (da)	2002-12-02	Præparater til behandling af perifere nuropatier indeholdende antidepressiver og/eller monoaminoxidase-inhibitorer og/eller vitamin B12 og/eller prekursere til eller inducere af en neurotransmitter
DK0869808T3 (da)	2006-11-13	Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
SG43768A1 (en)	1997-11-14	Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative dieases
NO960339L (no)	1996-03-26	Fremgangsmåte for å inhibere restenose
DK0646012T3 (da)	2003-03-03	Sårheling og behandling af fibrotiske sygdomme ved hjælp af TGFbeta-3
DK0509019T3 (da)	1999-04-19	Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin
DK0625050T3 (da)	1999-10-25	TGF-BETA til forbedring af regenerering af nervevæv
IS2216B (is)	2007-03-15	Meðferðaráform við inngjöf á H+,K+ -ATPasa-hemla
BR9509807A (pt)	1997-10-21	Composição líquida para administração oral e processo para tratar um mamífero incluindo o homem que esteja sofrendo de um quadro clinico mediado pela aç o do 5ht nos receptores 5ht3
DK0735868T3 (da)	2000-07-10	Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul
DK0379904T3 (da)	1996-09-16	Opløseligt molekyle, som er beslægtet med ICAM-1, men er forskelligt derfra
IS1665B (is)	1997-07-04	Nýjar króman og thíókróman afleiður
DE69400631D1 (de)	1996-11-07	Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose
EA199800317A1 (ru)	1998-10-29	СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
ES2175437T3 (es)	2002-11-16	Composicion de enalapril y losartan.
DK0859630T3 (da)	2003-03-24	Kombination af termozolomid og alfa-IFN til behandling af fremskreden cancer
DE69630761D1 (de)	2003-12-24	Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten
RU94033502A (ru)	1996-07-10	Способ лечения детей, больных вторичным панкреатитом
ATE138574T1 (de)	1996-06-15	Verwendung von prostaglandin f3alpha als okulares hypotensivum
EA200101043A1 (ru)	2002-04-25	Способ лечения неврологических или нейропсихиатрических расстройств
UA28288A (uk)	2000-10-16	Спосіб лікування шизофренії
CO4700451A1 (es)	1998-12-29	Dimaleato de n,n-dietil-8, 8-dipropil-2-azaspiro[4.5] decano-2-propanamina
DE69431731D1 (de)	2002-12-19	Orale oder intramuskuläre Behandlung von Pankreaskrebs durch wasserunlösliches S-Camptothecin mit geschlossenem Lactonring
UA41376C2 (uk)	2001-09-17	ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ